Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-505 in Advanced Solid Tumors
NCT07436728Phase 2Recruiting
- Sponsor
- Takeda
- Start
- May 2026
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-505 in solid tumor, sponsored by Takeda. Started May 2026; status: recruiting.
02
Drugs
TAK-505
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07436728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436728.